Cosmos Health (NASDAQ:COSM) CEO Buys $31,815.30 in Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas bought 51,315 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The shares were purchased at an average price of $0.62 per share, for a total transaction of $31,815.30. Following the completion of the purchase, the chief executive officer directly owned 6,271,813 shares of the company’s stock, valued at approximately $3,888,524.06. This trade represents a 0.82% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Grigorios Siokas also recently made the following trade(s):

• On Wednesday, November 19th, Grigorios Siokas purchased 61,614 shares of Cosmos Health stock. The shares were purchased at an average price of $0.65 per share, with a total value of $40,049.10.

Cosmos Health Stock Up 3.8%

Shares of COSM traded up $0.02 during midday trading on Friday, reaching $0.65. The stock had a trading volume of 64,294 shares, compared to its average volume of 612,875. The company has a market cap of $22.59 million, a price-to-earnings ratio of -0.86 and a beta of 5.32. The company’s fifty day simple moving average is $0.94 and its two-hundred day simple moving average is $0.71. Cosmos Health Inc. has a 1-year low of $0.28 and a 1-year high of $1.32. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.99 and a quick ratio of 0.82.

Cosmos Health (NASDAQ:COSM) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.16). The business had revenue of $17.11 million during the quarter, compared to analyst estimates of $16.40 million. Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. Equities research analysts expect that Cosmos Health Inc. will post -0.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on COSM shares. Wall Street Zen raised Cosmos Health to a “hold” rating in a research report on Saturday, September 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cosmos Health in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Investors Weigh In On Cosmos Health

A hedge fund recently raised its stake in Cosmos Health stock. Armistice Capital LLC lifted its holdings in Cosmos Health Inc. (NASDAQ:COSM) by 156.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,917,710 shares of the company’s stock after purchasing an additional 1,168,884 shares during the period. Armistice Capital LLC owned 7.03% of Cosmos Health worth $836,000 at the end of the most recent reporting period. Institutional investors own 12.61% of the company’s stock.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.